- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03107377
Phase 2B/3 Double-blinded Placebo-controlled
Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary: To determine if intravaginal EVO100 reduces the risk of urogenital Chlamydia trachomatis (CT) infection.
Secondary: To determine if intravaginal EVO100 reduces the risk of urogenital Neisseria gonorrhoeae (GC) infection.
Exploratory:To determine if EVO100 use rate (subject adherence to instructed use) has an effect on proportion of subjects who experience CT or GC infection during the study intervention period.
Primary Outcome Measures: Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT).
Secondary Outcome Measures: Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC).
Exploratory Outcome Measures:
- Compliance with EVO100 usage during study (rate of product use adherence).
- Sensitivity analyses of the primary parameter (proportion of subjects who experience at least one CT or GC infection during the study intervention period) will be performed for the following:
- Subjects with ≥20%, ≥40%, ≥60% and ≥80% product use adherence
- Subject Satisfaction
- Sexual satisfaction
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Coastal Clinical Research, Inc.
-
Mobile, Alabama, United States, 36608
- Mobile Ob-Gyn, PC
-
-
Arizona
-
Phoenix, Arizona, United States, 85015
- MedPharmics, LLC
-
Phoenix, Arizona, United States, 85032
- Precision Trials AZ, LLC
-
Tucson, Arizona, United States, 85745
- Eclipse Clinical Research
-
-
California
-
Arcadia, California, United States, 91007
- California Center for Clinical Research
-
Canoga Park, California, United States, 91303
- Hope Clinical Research
-
Huntington Park, California, United States, 90255
- United Clinical Research
-
San Diego, California, United States, 92108
- Medical Center for Clinical Research - Wake Research
-
San Francisco, California, United States, 94102
- Optimus Medical Group, Inc.
-
-
Colorado
-
Denver, Colorado, United States, 80202
- AFC Urgent Care Denver
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Planned Parenthood of Southern New England
-
-
Florida
-
Lauderdale Lakes, Florida, United States, 33319
- Precision Clinical Research
-
Miami, Florida, United States, 33135
- South Florida Research Center, Inc.
-
Miami Lakes, Florida, United States, 33014
- Panax Clinical Research
-
Miami Lakes, Florida, United States, 33016
- Global Health Research Center
-
Sarasota, Florida, United States, 34239
- Physician Care Clinical Research LLC
-
West Palm Beach, Florida, United States, 33409
- Comprehensive Clinical Trials, Llc
-
-
Georgia
-
Columbus, Georgia, United States, 31901
- Columbus Regional Research Institute - IACT Health
-
Lawrenceville, Georgia, United States, 30046
- Renew Health Clinical Research, LLC
-
Richmond Hill, Georgia, United States, 31324
- Meridian Clinical Research
-
-
Idaho
-
Nampa, Idaho, United States, 83687
- ASR, LLC
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- John H. Stroger Jr. Hospital of Cook County
-
-
Louisiana
-
Alexandria, Louisiana, United States, 71301
- DM Clinical Research
-
New Orleans, Louisiana, United States, 70124
- DelRicht Research
-
-
Michigan
-
Saginaw, Michigan, United States, 48602
- Valley OB-GYN
-
-
Mississippi
-
Biloxi, Mississippi, United States, 39531
- MedPharmics, LLD
-
Jackson, Mississippi, United States, 39213
- University of MS Medical Center
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Nevada Obstetrical Charity Clinic
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Bosque Women's Care
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Wake Research Associates, LLC
-
Salisbury, North Carolina, United States, 28144
- PMG Research of Salisbury
-
Wilmington, North Carolina, United States, 28401
- PMG Research, Inc. - Wilmington Health
-
-
Ohio
-
Cincinnati, Ohio, United States, 41073
- University of Cincinnati Physicians
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Planned Parenthood Southeastern Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213-3180
- Magee Womens Hospital of UPMC
-
-
South Carolina
-
West Columbia, South Carolina, United States, 29169
- Invocare Clinical Research Center
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- University of Tennessee Medical Center
-
Memphis, Tennessee, United States, 38120
- Adams Patterson OB/GYN, Medical Research Center of Memphis
-
-
Texas
-
Austin, Texas, United States, 78735
- Premier Family Physicians
-
Beaumont, Texas, United States, 77701
- Gadolin Research
-
Dallas, Texas, United States, 75204
- CityDoc Urgent Care
-
Houston, Texas, United States, 77081
- Texas Center for Drug Development, Inc.
-
Houston, Texas, United States, 77021
- Research Network America
-
Houston, Texas, United States, 77058
- Centex Studios, Inc.
-
Houston, Texas, United States, 77061
- Discovery MM Services, Inc.
-
Houston, Texas, United States, 77074
- S.E.Tx. Family Planning and Cancer Screening (SOGA)
-
Plano, Texas, United States, 75093
- North Texas Family Medicine
-
San Antonio, Texas, United States, 78212
- Neere Bhatia, MD OB/GYN
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- The Group for Women
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy female subjects between 18 and 45 years, inclusive
- Ability to understand the consent process and procedures
- Subjects agree to be available for all study visits
- Written informed consent in accordance with institutional guidelines
- Negative pregnancy test
- Negative CT and GC NAAT tests OR positive CT or GC NAAT and receives standard of care (SOC) treatment
- Agree to use a woman-controlled method of contraception, such as oral contraceptives, vaginal ring, birth control implants, IUDs, or tubal ligation (with the exception of spermicides, diaphragms, or any vaginally applied or inserted products containing nonoxynol-9). Condom use only is not an acceptable form of contraception for this study.
- Able and willing to comply with all study procedures
- Documented (as part of a retrievable medical record) CT or GC infection within 16 weeks prior to enrollment
- Reports vaginal sexual intercourse with a male partner at least 3 times per month in the previous month and anticipates vaginal sexual intercourse regularly for the duration of the study
Agree to abstain from douching or any form of vaginal suppository use (other than study product) during course of study
-
Exclusion Criteria:
- Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
- In the opinion of the Investigator, have a history of substance abuse in the last 12 months
- In the opinion of the Investigator, have issues, conditions, or concerns that may compromise the safety of the subject, impact the subject's compliance with the protocol requirements, or confound the reliability of the data acquired
- Be an Evofem, ClinicalRM, or clinical site employee regardless of direct involvement in research activities, or their close relative
- Pregnant (or actively trying to become pregnant), or breast-feeding
- Women who have undergone a total hysterectomy (had uterus and cervix removed)
- Inability to provide informed consent
- A subject with a history or expectation of noncompliance with medications or intervention protocol
- Have engaged in sexual intercourse, douching or used of any form of vaginal suppository or intravaginal device for 24 hours prior to enrollment (may be enrolled at a later date if all other criteria are met)
- Menstruating at enrollment (may be enrolled at a later date if all other criteria are met)
Women who are currently being treated, or have been treated, for a period of 14 days prior to enrollment, with specific antibiotics known to be used for the treatment of CT or GC:
- Azithromycin
- Erythromycin
- Tetracycline
- Minocycline
- Doxycycline
- Levofloxacin
- Ofloxacin
- Ceftriaxone
- Cefixime
- In the opinion of the Investigator, has signs/symptoms that indicate persistence of chlamydia or gonorrhea infection diagnosed at screening, new interval infection and/or a failure to comply with or complete the prescribed treatment regimen following a positive screening NAAT.
- Women who regularly use douches, vaginal medications, products, or suppositories
- Women who are currently using contraceptive products that are directly delivered to the vaginal mucosa, such as diaphragms, vaginal rings (e.g. NuvaRing®), spermicides, or any vaginally applied or inserted products containing nonoxynol-9.
- Children, pregnant women, prisoners, and other vulnerable populations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: EVO100
A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate.
5 g intravaginally applied at least one hour prior to vaginal intercourse.
|
5 g dose applied up to 1 hour prior to coitus
|
Placebo Comparator: Placebo
An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water.
5 g intravaginally applied at least one hour prior to vaginal intercourse.
|
5 g dose applied up to 1 hour prior to coitus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urogenital CT Infection
Time Frame: 16 weeks
|
Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT).
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urogenital GC Infection
Time Frame: 16 weeks
|
Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC).
|
16 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance With EVO100 and Sensitivity Analyses (Part I)
Time Frame: 16 weeks
|
Summary of Coital Events during treatment
|
16 weeks
|
Subject Satisfaction With Product
Time Frame: 16 weeks
|
The proportion of subjects who experienced at least one CT infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.
|
16 weeks
|
Sexual Satisfaction
Time Frame: 16 weeks
|
The proportion of subjects who experienced at least one GC infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.
|
16 weeks
|
Compliance With EVO100 and Sensitivity Analyses
Time Frame: 16 weeks
|
The proportion of subjects who experienced at least one CT infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.
|
16 weeks
|
Compliance With EVO100 and Sensitivity Analyses
Time Frame: 16 weeks
|
The proportion of subjects who experienced at least one GC infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.
|
16 weeks
|
Compliance With EVO100 and Sensitivity Analyses (Part II)
Time Frame: 16 weeks
|
Summary of number of applicators used via eDiary
|
16 weeks
|
Compliance With EVO100 and Sensitivity Analyses (Part III)
Time Frame: 16 weeks
|
Study product adherence
|
16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Kelly Culwell, MD, Evofem Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EVO-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chlamydia Trachomatis Infection
-
Region ÖstergötlandUnknownChlamydia Trachomatis Genital Infection | Chlamydia Trachomatis Infection of Anus and RectumSweden
-
Maastricht University Medical CenterCompletedChlamydia Trachomatis InfectionNetherlands
-
University Hospital, BordeauxUSC EA 3671 Infections humaines à mycoplasmes et à chlamydiaeUnknownChlamydia Trachomatis Infection | Vaginal Infection | Anal InfectionFrance
-
Maastricht University Medical CenterNational Institute for Public Health and the Environment (RIVM); ZonMw: The... and other collaboratorsCompletedChlamydia Trachomatis InfectionNetherlands
-
ActivBiotics Pharma, LLCCompletedSafety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in WomenChlamydia Trachomatis InfectionUnited States
-
Warner ChilcottCompletedUrogential Chlamydia Trachomatis InfectionUnited States
-
D.O. Ott Research Institute of Obstetrics, Gynecology...Active, not recruitingInfertility | Chlamydia Trachomatis Infection | Antichlamydial Antibodies | Tubal Factor InfertilityRussian Federation
-
Haiphong University of Medicine and PharmacyCompletedChlamydia Trachomatis Infection | Neisseria Gonorrhoeae InfectionVietnam
-
NeuMoDx Molecular, Inc.NAMSACompletedNeisseria Gonorrheae Infection | Chlamydia Trachomatis InfectionUnited States
-
Obafemi Awolowo University Teaching HospitalCompleted
Clinical Trials on EVO100
-
Evofem Inc.CompletedSexually Transmitted Diseases | Chlamydia | GonorrheaUnited States